$SCL

STEPAN CO (SCL): Results of Operations and Financial Condition

STEPAN CO (SCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d139905dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stepan Reports Second Quarter 2026 Results Northbrook, Illinois, July 29, 2026 — Stepan Company (NYSE: SCL) today reported: Second Quarter 2026 Highlights • Reported net income was $22.9 million, up 102% versus the prior ye

Original reporting
Published Jul 29, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$SCL
Neutral
medium confidence
Mentioned
$SCL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SCLNeutralMed
01

Why it matters

Traders can update expectations for 2H 2026 earnings and cash flow based on the stated restructuring charge range ($75.0 to $80.0M) and cash impact ($14.0 to $18.0M), while also tracking whether working-capital pressures ease after the quarter.

02

Market read

Strong adjusted profitability and volume growth are tempered by negative free cash flow and sizable restructuring charges expected to land mostly in 2H 2026.

03

What to watch

The filing notes most restructuring expense is expected in 2H 2026; investors may need to model earnings and cash flow timing rather than annual totals alone.

Relevance 7/10Novelty 7/10Timing: after-hours filing of Q2 2026 results and updated 2026 restructuring charge outlook

Background

The 8-K includes Q2 2026 operating results and an update tied to Project Catalyst efficiency actions, including site closure-related restructuring and workforce reductions.

Company-level read

Ticker impact

$SCLNeutralMedium confidence
Context

Stepan’s 8-K reports Q2 results plus a Project Catalyst plan to cut about 100 salaried roles and expects $75.0 to $80.0M full-year restructuring charges.

Expected impact

Likely near-term volatility as investors weigh margin/volume strength against cash flow weakness and the magnitude/timing of restructuring charges.

Evidence & confidence

The filing provides multiple decision-relevant datapoints: net income and adjusted EBITDA up sharply, FCF negative with a working-capital explanation, and explicit restructuring charge range and cash impact for 2026.

Market effects

Improved Surfactant and Polymer volumes and margin recovery may support sentiment for industrial specialty chemicals demand, while restructuring and cash conversion highlight execution risk.

No specific regional demand shock is disclosed; foreign currency translation is a modest positive driver of net sales.

Mentions customer pre-buys tied to geopolitical uncertainty, suggesting demand timing effects that could normalize in later quarters.

Counterpoint

Adjusted earnings and EBITDA strength may be partially offset by cash conversion issues, with working-capital needs and restructuring cash impacts potentially pressuring near-term liquidity.

Key entities

  • Stepan Company

    Reports Q2 2026 results, Project Catalyst workforce reduction, and full-year restructuring charge and cash impact guidance.

Related articles

$SCLMed

Stepan Company Q2 2026 Earnings Call Summary

Strategic Performance Drivers Adjusted EBITDA growth of 45% was driven by a combination of 6% organic volume growth, disciplined pricing execution, and ramping productivity gains. Surfactant performance benefited from broad-based demand across all end markets, specifically led by industrial cleaning, laundry, and oil field sectors. Margin recovery was achieved through the rigorous application of contractual pass-through mechanisms and pricing actions to offset fluctuating raw material costs.

$SCLMedAI 8/10

Stepan Reports Second Quarter 2026 Results

Stepan (NYSE: SCL) reported Q2 2026 net income of $22.9M, up 102% year over year, and adjusted net income of $27.1M, up 126%. Adjusted EBITDA rose 45% to $74.4M. Net sales increased 15% to $684.1M, with organic volume up 6%. Free cash flow was -$15.0M due to working capital. The company plans to cut about 100 salaried roles under Project Catalyst and expects full-year restructuring charges of $75.0M-$80.0M.

$RYMMedAI 8/10

Daily NZX update, Wednesday, June 3, 2026

NZX50 was down 0.3% at 3:00pm, though up 0.4% over five sessions and 6.5% over 12 months. Gentrack Group led gainers (+4%), while Vista Group fell the most (-3%). Ebos (-3%) and A2 Milk (-1%) also declined. Ryman Healthcare is considering new six-year secured bonds; Scales Corp declared a 12.5c FY2025 final dividend; Pacific Edge raised NZ$36.1m at NZ$0.17/share.

$SCLHighAI 9/10

Daily NZX update, Wednesday, May 27, 2026

The NZX50 rose 0.7% to extend gains to 3.1% over five days and 3.1% for the month (still down 2.0% over six months; up 4.6% YoY). Kathmandu Holdings jumped 14% and KMD reported Q3 FY26 sales +5.2% YoY and gross margin 58.2% (+258 bps). Vista Group gained 4% on a new five-year Cinemex deal; PaySauce revenue rose 3% to $9.2m.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.

$BRK-BMed

Berkshire Hathaway Just Did Something It Hasn’t Done in More Than 3 Years

Berkshire Hathaway reported Q2 2026 cash and Treasury bills of $365.5 billion, down from $397.4 billion in Q1, ending a 14-quarter streak as a net seller. According to Berkshire, CEO Greg Abel became a net buyer of equities, adding about $20 billion net, and increased buybacks to $4.5 billion. Apple fell to 20% of the portfolio; Alphabet rose after a $10 billion investment.